Exact Mass: 470.1577
Exact Mass Matches: 470.1577
Found 163 metabolites which its exact mass value is equals to given mass value 470.1577
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
7-hydroxymethotrexate
7-hydroxymethotrexate is a metabolite of methotrexate. Methotrexate, abbreviated MTX and formerly known as amethopterin, is an antimetabolite and antifolate drug. It is used in treatment of cancer, autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions. It acts by inhibiting the metabolism of folic acid. Methotrexate began to replace the more toxic antifolate aminopterin starting in the 1950s. The drug was developed by Yellapragada Subbarao. (Wikipedia) D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists
3-Carboxylic acid-picumast
Alvaradoin M
A C-glycosyl compound that is 1,8-dihydroxy-3-methylanthracen-9(10H)-one substituted by a 3-O-senecioyl-alpha-L-lyxopyranosyl moiety at position 10 via a C-glycosidic linkage (the 10S stereoisomer). It is isolated from the leaves of Alvaradoa haitiensis and exhibits cytotoxicity against human oral epidermoid carcinoma.
Alvaradoin L
A C-glycosyl compound that is 1,8-dihydroxy-3-methylanthracen-9(10H)-one substituted by a 2-O-senecioyl-alpha-lyxopyranosyl moiety at position 10 via a C-glycosidic linkage (the 10S stereoisomer). It is isolated from the leaves of Alvaradoa haitiensis and exhibits cytotoxicity against human oral epidermoid carcinoma.
2-(1,3-Benzodioxol-5-yl)-3,5,6,8-tetramethoxy-7-[(3-methyl-2-butenyl)oxy]-4H-1-benzopyran-4-one
7-Hydroxymethotrexat
D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists CONFIDENCE standard compound; INTERNAL_ID 2731 CONFIDENCE standard compound; INTERNAL_ID 8505
Ala Cys Phe Met
Ala Cys Met Phe
Ala Phe Cys Met
Ala Phe Met Cys
Ala Met Cys Phe
Ala Met Phe Cys
Cys Ala Phe Met
Cys Ala Met Phe
Cys Cys Phe Val
Cys Cys Val Phe
Cys Asp His Pro
Cys Asp Pro His
Cys Phe Ala Met
Cys Phe Cys Val
Cys Phe Met Ala
Cys Phe Val Cys
Cys His Asp Pro
Cys His Pro Asp
Cys Met Ala Phe
Cys Met Phe Ala
Cys Pro Asp His
Cys Pro His Asp
Cys Val Cys Phe
Cys Val Phe Cys
Asp Cys His Pro
Asp Cys Pro His
Asp His Cys Pro
Asp His Pro Cys
Asp Pro Cys His
Asp Pro His Cys
Asp Ser Ser Tyr
Asp Ser Tyr Ser
Asp Tyr Ser Ser
Phe Ala Cys Met
Phe Ala Met Cys
Phe Cys Ala Met
Phe Cys Cys Val
Phe Cys Met Ala
Phe Cys Val Cys
Phe Met Ala Cys
Phe Met Cys Ala
Phe Val Cys Cys
His Cys Asp Pro
His Cys Pro Asp
His Asp Cys Pro
His Asp Pro Cys
His Pro Cys Asp
His Pro Asp Cys
Met Ala Cys Phe
Met Ala Phe Cys
Met Cys Ala Phe
Met Cys Phe Ala
Met Phe Ala Cys
Met Phe Cys Ala
Pro Cys Asp His
Pro Cys His Asp
Pro Asp Cys His
Pro Asp His Cys
Pro His Cys Asp
Pro His Asp Cys
Ser Asp Ser Tyr
Ser Asp Tyr Ser
Ser Ser Asp Tyr
Ser Ser Tyr Asp
Ser Tyr Asp Ser
Ser Tyr Ser Asp
Val Cys Cys Phe
Val Cys Phe Cys
Val Phe Cys Cys
Tyr Asp Ser Ser
Tyr Ser Asp Ser
Tyr Ser Ser Asp
7-Hydroxymethotrexate
D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists
1-[[2-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid methyl ester
7-[2-(1,3-Benzothiazol-2-ylthio)ethyl]-1,3-dimethyl-8-(3-methyl-1-piperidinyl)purine-2,6-dione
N-(2-furanylmethyl)-2-[[oxo-(3,4,5-trimethoxyphenyl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide
Alvaradoin K
A C-glycosyl compound that is 1,8-dihydroxy-3-methylanthracen-9(10H)-one substituted by a 2-O-senecioyl-alpha-lyxopyranosyl moiety at position 10 via a C-glycosidic linkage (the 10R stereoisomer). It is isolated from the leaves of Alvaradoa haitiensis and exhibits cytotoxicity against human oral epidermoid carcinoma.
5-Formimidoyltetrahydrofolate(2-)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
3-[2-(tert-butylamino)-2-oxoethoxy]-N-(4-chloro-2,5-dimethoxyphenyl)-2-naphthalenecarboxamide
4-(3,5-dimethyl-1-pyrazolyl)-N-[2-methoxy-5-(4-morpholinylsulfonyl)phenyl]benzamide
(2S)-3-(1H-indol-3-yl)-2-[[2-(4-methyl-6-oxobenzo[c]chromen-3-yl)oxyacetyl]amino]propanoic acid
N-[[(4S,5S)-8-(2-cyclopropylethynyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4S,5S)-8-(2-cyclopropylethynyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
(6R,7S,8R)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
N-[[(4R,5S)-8-(2-cyclopropylethynyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4R,5R)-8-(2-cyclopropylethynyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4R,5S)-8-(2-cyclopropylethynyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4S,5R)-8-(2-cyclopropylethynyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4R,5R)-8-(2-cyclopropylethynyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4S,5R)-8-(2-cyclopropylethynyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
(6S,7S,8S)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8S)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
methyl 2-[(5E)-5-[(3,4-diethoxyphenyl)methylidene]-3-(4-methoxyphenyl)-4-oxo-2-sulfanylideneimidazolidin-1-yl]acetate
[(2->6)-alpha-D-glucosyl-(1->4)-N-acetyl-alpha-D-neuraminosyl]n
5-Formimidoyltetrahydrofolate(2-)
Dianion of 5-formimidoyltetrahydrofolic acid arising from deprotonation of both carboxylic acid functions.
AZD1283
AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders[1][2].
SF-22
SF-22 is a potent and brain-penetrant antagonist of neuropeptide Y receptor (Y2R), with the IC50 value of 750 nM. SF-22 plays an important role in neurological disease[1].